NEW YORK, March 3, 2017 /PRNewswire/ --
For today, Stock-Callers.com follows the recent performances of these Biotech
Menlo Park, California-based Geron Corp.'s shares rose 3.29%, closing Thursday's trading session at $2.20. The stock recorded a trading volume of 2.19 million shares, which was above its three months average volume of 1.38 million shares. The Company's shares have advanced 5.77% in the last month, 5.77% over the previous three months, and 6.28% since the start of this year. The stock is trading 3.80% above its 50-day moving average. Additionally, shares of Geron, which focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies, have a Relative Strength Index (RSI) of 53.49.
On March 02nd, 2017, Geron announced that an abstract submitted by Janssen Research & Development, LLC describing non-clinical data on imetelstat has been accepted for presentation as a poster at the 2017 American Association for Cancer Research Annual Meeting to be held in Washington, D.C. from April 01st-05th, 2017. Access our complete research report on GERN for free at:
On Thursday, Wilmington, Delaware headquartered Incyte Corp.'s stock recorded a trading volume of 1.96 million shares, and ended the day 0.32% lower at $132.80. The Company's shares have advanced 9.56% in the last month, 26.39% in the previous three months, and 32.44% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.51% and 40.02%, respectively. Furthermore, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 71.50.
On March 02nd, 2017, Incyte announced that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research annual meeting in Washington, D.C. from April 01st-05th, 2017. These abstracts include a clinical data presentation from the dose-escalation phase of the Company's ongoing trial of its selective FGFR 1/2/3 inhibitor (INCB54828), and well as preclinical data from its small molecule inhibitor programs targeting PI3K? (INCB50465), LSD1 (INCB59872), JAK1 (INCB52793), BRD/BET (INCB54329 and INCB57643) and FGFR4 (INCB62079) and from its epacadostat, OX40 (INCAGN1949) and GITR (INCAGN1876) immuno-oncology programs.
Yesterday, research firm Instinet initiated a 'Buy' rating on the Company's stock, with a target price of $148 per share. The complimentary research report on INCY can be downloaded at:
San Diego, California headquartered Illumina Inc.'s stock finished the day 0.64% lower at $167.72 with a total trading volume of 804,875 shares. The Company's shares have gained 4.76% in the last one month, 22.84% in the previous three months, and 30.99% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.57% and 10.77%, respectively. Additionally, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 70.10.
On February 28th, 2017, Illumina announced the launch of the iHope Network, a consortium of member institutions who have committed to providing clinical whole genome sequencing to underserved families. As of the day of official press release, the iHope Network consists of clinical laboratory members: Illumina, Genome.One, GeneDx, HudsonAlpha, and their affiliate healthcare partners. Register for free on Stock-Callers.com and get access to the latest PDF format report on ILMN at:
Shares in Warren, New Jersey headquartered Bellerophon Therapeutics Inc. ended yesterday's session 2.31% higher at $1.33. The stock recorded a trading volume of 964,661 shares. The Company's shares have skyrocketed 104.62% in the last one month, 177.08% over the previous three months, and 155.77% since the start of this year. The stock is trading 76.11% and 7.10% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Bellerophon Therapeutics, which focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases, have an RSI of 63.81.
On January 04th, 2017, Bellerophon Therapeutics announced that it received confirmation from the US Food and Drug Administration of the Agency's acceptance of all modifications proposed by the Company to its Phase-3 program for INOpulse in Pulmonary Arterial Hypertension. Download your free research report on BLPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All